Abstract

Nanomaterials engineered for drug delivery penetrate the blood-brain barrier, ensuring direct access to cancerous cells, including carbon nanodots, liposomes, dendrimers, metallic nanoparticles, etc. By encapsulating therapeutic agents, nanomaterials enhance their stability and bioavailability, optimizing treatment efficacy. Furthermore, they enable real-time monitoring of treatment response, facilitating adjustments as needed. This strategy represents a significant advancement in oncology, offering a promising avenue for improving outcomes in brain cancer patients by maximizing therapeutic benefits while minimizing adverse effects. The discovery and development of novel nanomaterials and drug delivery systems based on nanotechnology are thus interesting topics for researchers working on the delivery of drugs to the brain and central nervous system. However, several challenges may be encountered in the development of nanomaterials and the commercialization of products. Further, the therapeutic outcomes may vary between patients. Thus, personalized therapy design for the delivery of nanomedicine may be a better option. The integration of personalized nanoparticle-based therapies holds great potential for transforming the landscape of brain cancer management, heralding a new era. Personalized therapy utilizing nanomaterials is revolutionizing brain cancer treatment by targeting tumours with precision while minimizing systemic toxicity. This approach tailors therapeutic interventions to individual patient profiles, accounting for tumor heterogeneity and patient-specific responses.

Keywords: Brain cancer, nanomaterials, personalized therapy, optimized treatment.